Abstract
Trans-regulation of G protein-coupled receptors (GPCRs) by leucine-rich repeat (LRR) transmembrane proteins has emerged as a novel type of synaptic molecular interaction in the last decade. Several studies on LRR–GPCR interactions have revealed their critical role in synapse formation and in establishing synaptic properties. Among them, LRR–GPCR interactions between extracellular LRR fibronectin domain-containing family proteins (Elfn1 and Elfn2) and metabotropic glutamate receptors (mGluRs) are particularly interesting as they can affect a broad range of synapses through the modulation of signaling by glutamate, the principal excitatory transmitter in the mammalian central nervous system (CNS). Elfn–mGluR interactions have been investigated in hippocampal, cortical, and retinal synapses. Postsynaptic Elfn1 in the hippocampus and cerebral cortex mediates the tonic regulation of excitatory input onto somatostatin-positive interneurons (INs) through recruitment of presynaptic mGluR7. In the retina, presynaptic Elfn1 binds to mGluR6 and is necessary for synapse formation between rod photoreceptor cells and rod-bipolar cells. The repertoire of binding partners for Elfn1 and Elfn2 includes all group III mGluRs (mGluR4, mGluR6, mGluR7, and mGluR8), and both Elfn1 and Elfn2 can alter mGluR-mediated signaling through trans-interaction. Importantly, both preclinical and clinical studies have provided support for the involvement of the Elfn1–mGluR7 interaction in attention-deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), and epilepsy. In fact, Elfn1–mGluR7-associated disorders may reflect the altered function of somatostatin-positive interneuron inhibitory neural circuits, the mesolimbic and nigrostriatal dopaminergic pathway, and habenular circuits, highlighting the need for further investigation into this interaction.
Introduction
G protein-coupled receptors (GPCRs) are important targets for drugs in neuropsychiatric disorders (Hauser et al., ; Ehrlich et al., )1. Based on a sequence comparison, the GPCR superfamily has been classified into five main families, namely, rhodopsin (class A), adhesion (class B), secretin (class B), glutamate (class C), and frizzled/taste2 (class D); (Lagerstrom and Schioth, ; Gacasan et al., ). The conventional concept of GPCR signaling, which includes ligand binding, a conformational change in the GPCR followed by activation of G proteins affecting effectors, may be interpreted as transformation and amplification of extracellular signals into intracellular ones. However, this idea is challenged by the presence of extracellular binding partners for GPCRs.
For example, some of the GPCRs in the adhesion group (class B) are extracellularly bound by single-transmembrane receptors [in-trans: teneurin 1–4, neurexin 1–3, fibronectin leucine-rich transmembrane 1–3 (Flrt1–Flrt3); in cis: contactin 6, stabilin 2, and neuroligin] and extracellular matrix proteins (Knapp and Wolfrum, ; Dunn et al., ). The extracellular interactions of GPCRs in the adhesion group are involved in synaptogenesis, neurite outgrowth, and axon guidance. In particular, latrophilins (Lphns and Adgrls) play a role in controlling glutamatergic synapse density (Lphn3, O’Sullivan et al., ) and specificity of synaptic connection (Lphn2 and Lphn3, Sando et al., ) through a trans-interaction with Flrt3 and/or teneurins in mice.
Flrt proteins are leucine-rich repeat (LRR) and fibronectin type III domain-containing transmembrane proteins (LRRFn) and are similar to the extracellular LRR fibronectin domain-containing family of proteins (Elfn1 and Elfn2) in terms of domain organization (Figure 1A; Dolan et al., ). Elfn proteins have been shown to trans-interact with the glutamate (class C) family of GPCRs (Tomioka et al., ; Cao et al., , ; Dunn et al., , ) that are distantly located from the adhesion (class B) family in the human GPCR molecular phylogeny (Figure 1B; Fredriksson et al., ). Therefore, the trans-regulation of GPCRs by Flrt and Elfn family proteins is thought to occur independently during evolution. However, interestingly, the trans-interaction of the two classes of GPCR–LRRFn plays a role in closely related neural circuits (Figures 1C–G). Since there have been detailed reviews about Lphn3– or Lphn3–Flrt3 interaction (Figure 1G; Ranaivoson et al., ; Knapp and Wolfrum, ; Dunn et al., ; Bruxel et al., ), this article is focused on the Elfn–mGluR interaction and its relevance to Flrt–Lphn trans-interaction.
Figure 1
Elfn Proteins
The names “Elfn1” and “Elfn2” were proposed in a bioinformatic analysis focusing on the extracellular LRR motif (Dolan et al., ) and are currently used in the name for human orthologues2. Figure 1A illustrates the domain structure of Elfn1 and Elfn2 proteins (Dolan et al., ). In subcellular fractionation studies, both Elfn1 and Elfn2 have been recovered in synaptosomal plasma membrane and postsynaptic density fractions (Tomioka et al., ; Dunn et al., ), while Elfn1 was undetectable in the synaptic vesicle fraction (Tomioka et al., ).
In mice, Elfn1 expression increases in the brain during postnatal development (Tomioka et al., ). In the adult brain, Elfn1 expression is strongly detected in the cerebral cortex, hippocampus (Figure 1C), habenular nuclei, septum, diagonal bands, anterior amygdaloid area, globus pallidus, and medial forebrain bundles and moderately in the substantial nigra, ventral tegmental nucleus, fasciculus retroflexus, and lateral subnucleus of the interpeduncular nucleus (IPN; Dolan and Mitchell, ; Tomioka et al., ). Elfn1 mRNA is detected in a punctate pattern, corresponding to the distribution of interneurons (INs). In addition to the spotty expression in the hippocampus and cerebral cortex, Elfn1 mRNA is densely distributed in the septum, diagonal bands, habenular nucleus, globus pallidus, retrorubral area of midbrain (containing the A8 dopaminergic cell group), and hippocampal subiculum (Allen Mouse Brain Atlas; Lein et al., ).
At the cellular level, Elfn1 is strongly expressed in INs of the hippocampus and cerebral cortex (Dolan et al., ). In hippocampal neuron culture, 96% of the Elfn1-positive neurons were GAD67 positive, and 35% of the GAD67-positive cells were Elfn1 positive. Elfn1 expression occurs in somatostatin INs (SST-INs) and is localized to the dendrites. More than 85% of the Elfn1-positive neurons were SST immunopositive in the CA1, CA3, and DG regions. Conversely, nearly all SST-INs were immunopositive for Elfn1 (Tomioka et al., ). SST-INs of the hippocampus include oriens-lacunosum moleculare (OLM) cells in the CA1 region and hilar perforant path-associated (HIPP) cells in the dentate gyrus.
In an RNA sequencing-based transcriptome database3, the Elfn1 transcript is most abundant in hippocampal and cortical SST-INs (TEINH19, 1.9) and second most abundant in cholinergic neurons (DECHO1, 1.4) located in the medial septal nucleus, diagonal band nucleus, and nucleus basalis of Meynert. A modest level of Elfn1 expression can be seen in cholinergic neurons of the striatum, amygdala, cerebral cortex (TECHO, 0.88), and habenular nucleus (DECHO2, 0.33) as well as GABAergic neurons in the medial septal nucleus and magnocellular nucleus (TEINH1, 0.84).
Elfn2 protein levels in brain subregions are correlated with those of mRNA in immunoblot (Dunn et al., ). Although the immunostaining of Elfn2 has not been reported, Elfn2 mRNA in adult mice is strongly distributed in the hippocampal pyramidal neurons, dentate gyrus granule neurons, cortex, cerebral cortex layer II/III neurons, accessory olfactory nucleus, and the olfactory bulb, while moderate to weak expressions can be observed broadly in the cerebral cortex, the striatum, the thalamus, the midbrain, and cerebellar Purkinje cells (Allen Mouse Brain Atlas; Lein et al., ). In terms of cell type, the Elfn2 transcript is broadly distributed across both excitatory and inhibitory neurons in the hippocampus and cerebral cortex (Dunn et al., ). Neurons strongly expressing Elfn1 also moderately express Elfn2 (TEINH19, 0.30; DECHO1, 0.35)3.
Trans-Synaptic Interaction with Mglurs
The function of Elfn1 was first identified in a hippocampal glutamatergic synapse between pyramidal neurons and OLM INs (hereafter pyramidal-to-OLM synapse; Sylwestrak and Ghosh, ). Postsynaptic Elfn1 in OLM INs regulates presynaptic release probability, conferring target-specific synaptic properties to pyramidal cell axons (Sylwestrak and Ghosh, ).
The molecular mechanism underlying Elfn1-mediated presynaptic regulation includes a trans-synaptic interaction between postsynaptic Elfn1 and presynaptic mGluR7 (Figure 1; Tomioka et al., ). Interestingly, mGluR7 has been shown to be densely distributed in postsynaptic pyramidal-to-OLM cells (Shigemoto et al., ). One study using an Elfn1-knockout (KO) model found that pyramidal-to-OLM synapses lacked mGluR7-immunopositive signals (Figure 1H) and that heterotopic expression or overexpression of Elfn1 recruited mGluR7-positive signals (Tomioka et al., ). Accordingly, short-term facilitation of pyramidal-to-OLM synapses is reduced in the hippocampus of Elfn1-KO mice (Tomioka et al., ).
In addition to pyramidal-to-OLM synapses, Elfn1 is essential for the formation of synapses between rods and rod ON-bipolar cells in the primary rod pathway (Figures 1I,J). In this synapse, presynaptic Elfn1 exists in rods and binds in transsynaptic to postsynaptic mGluR6 on rod ON-bipolar cells (Figure 1J; Cao et al., ). Elfn1-KO mice lack the functional connection for rod-photoreceptor cells in the retina, resulting in night blindness-like behavioral abnormalities (Cao et al., ). The binding of Elfn1 with mGluR6 is proposed to play an essential role in the formation of the synaptic contact, as elimination of either component results in a similar loss of synapses (Cao et al., ). Furthermore, ELFN2 that directly associates with mGluR6 is pivotal for the functional wiring cones with cone ON bipolar cells (Cao et al., ). In mouse retinal development, Elfn1 and Elfn2 show distinct developmental expression profiles and synergistically control the functional wiring of cones with cone ON-bipolar cells (Cao et al., ; Figures 1I,K). In the combination of studies on pyramidal-to-OLM synapses and on retinal photoreceptor-bipolar cell synapses, Elfn proteins are necessary for both synapse formation and functional specification and can be mGluR trans-binding partners on both the presynaptic and postsynaptic sides.
The above studies raise the possibility that Elfn proteins can be versatile trans-binding partners for mGluRs. In the human genome, there are eight mGluRs that can be divided into three classes based on their structural and functional features (Figure 1B; Conn and Pin, ). The repertoire of Elfn1 binding partners has been characterized by Dunn et al. (). Their results indicate that ELFN1 selectively binds all group III mGluRs (mGluR4, mGluR6, mGluR7, and mGluR8), but not the other mGluR species (Figure 1B; Dunn et al., ). Elfn2 was also shown to bind group III mGluRs (mGluR4, mGluR6, mGluR7, and mGluR8; Dunn et al., ; Cao et al., ).
Elfn–Mglur Trans-Interaction in Target-Specific Synaptic Properties
As described above, the trans-interaction with group III mGluR autoreceptors is a common feature of Elfn1 and Elfn2. Meanwhile, Elfn1 and Elfn2 selectively modulate the inhibitory tone mediated by GABAergic INs and the excitatory input, respectively. The first electrophysiological analysis was performed after OLM cells-specific knockdown by Elfn1 short-hairpin RNA interference (Sylwestrak and Ghosh, ). Excitatory postsynaptic potentials and short-term facilitation were decreased in Elfn1-reduced OLM cells; however, there were no change in postsynaptic properties such as the decay kinetics of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)- and N-methyl-D-aspartate receptor (NMDAR)-mediated components. Furthermore, the Elfn1-reduced OLM cells showed a significant increase in initial release probability at early stimuli in the train compared to uninfected cells. Targeting of the synapse by SST cells and suppression of the excitatory presynaptic signal regulated by Elfn1 are mediated by a trans-synaptic interaction with presynaptic mGluR7 (Figure 1E; Tomioka et al., ), and Elfn1 KO mice also showed a similar electrophysiological response to the Elfn1-reduced cells (Tomioka et al., ).
Recently, it was revealed that the Elfn1–mGluR7 interaction contributes to the difference in the responsiveness of SST cells in cerebral cortex layer structures (Stachniak et al., ). Target cell-specific synaptic release of pyramidal cells to OLM cells is determined by the presence or absence of kainate receptors containing a glutamate receptor, ionotropic, kainite 2 subunit (GluK2-KARs) in presynaptic excitatory pyramidal cells. Recruitment of GluK2-KARs is mediated by presynaptic mGluR7 clustering through an interaction with Elfn1 (Figure 2A). In cerebral cortex layer 2/3 SST-INs, early synaptic suppression with mGluR7 is followed by late synaptic facilitation with GluK2-KARs to generate a strongly facilitating synapse. In contrast, GluK2-KARs do not contribute to synaptic facilitation of cerebral cortex layer 5 SST-INs; therefore, Elfn1-mediated clustering and activation of mGluR7 generates moderate synaptic facilitation in the layer 5 SST-INs.
Figure 2
Elfn proteins act as a negative allosteric modulator for the group III mGluR ligand and can alter both agonist-induced and constitutive receptor activities (Dunn et al., , ). As a mechanism of receptor activity regulation by Elfn, it was shown that Elfn1 recruits mGluR7 in the presynaptic membrane and generates constitutive mGluR7 activity via its dimerization (Figure 2A) in an electrophysiological analysis of cortical slices (Stachniak et al., ). Homodimerization and heterodimerization of mGluRs expand signaling diversity and tune responsiveness (Kammermeier, ; Levitz et al., ). Stachniak et al. () revealed that Elfn1 clusters mGluR7, which results in constitutive suppression of initial release (Figure 2A). A group III mGluR-selective antagonist methylserine-O-phosphate (MSOP) caused de-suppression of low initial release in wild-type (WT) slices; however, there was no effect in the Elfn1 KO slices (Stachniak et al., ). A group III mGluR-selective agonist L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) has no further suppressive effect on initial release in WT slices but suppresses the late release in both WT and KO slices (Stachniak et al., ).
The role of the Elfn2–mGluR interaction has been investigated using electrophysiological analysis in the hippocampus of Elfn2-KO mice (Dunn et al., ). Importantly, Elfn2 is expressed in hippocampal pyramidal neurons and is mainly distributed in postsynapse (Figures 1F; Figure 2B). In the CA1 of Elfn2-KO mice, both the amplitudes and slopes of field excitatory postsynaptic potentials from the stratum radiatum by stimulated glutamate release from Schaffer collaterals were increased compared to those in WT mice (Dunn et al., ). Together with additional results, Elfn2 is proposed to inhibit glutamatergic transmission in the hippocampus (Figure 2B; Dunn et al., ).
Significance of Elfn-Mglur Trans-Interaction in Pathophysiology
Roles for the Elfn–mGluR interaction in higher brain functions have been suggested based on the phenotypes of Elfn-KO and mGluR-KO mice. Elfn1-KO mice exhibit hyperactivity and adult-onset (11 weeks or older) sensory-triggered epileptic seizures (Tomioka et al., ). In particular, the latter phenotype is similar to that of mGluR7-KO mice in that both Elfn1- and mGluR7-KO mice show myoclonic jerks and forelimb clonus that are sometimes tonic in nature, a Racine scale score of 2–5, and sign onset at around 10 weeks old (mGluR7 KO; Sansig et al., ; Fisher et al., ) or 11 weeks old (Elfn1 KO).
The similarity between the Elfn1 KO and mGluR7 KO has been extended to pharmaco-behavioral studies. For example, the effects of amphetamine on locomotor activity in the open-field test are altered in Elfn1−/− (homozygote of LacZ-neo-knockin mutation) in comparison to Elfn1+/– (heterozygote of LacZ-neo-knockin mutation) mice (Dolan and Mitchell, ). Furthermore, mGluR7-KO (LacZ-knockin) mice exhibit an attenuated response to amphetamine (Fisher et al., ).
Elfn2-KO (LacZ-neo-knockin mutation) mice show various behavioral abnormalities including increased seizure susceptibility, hyperactivity, increased anxiety, increased compulsivity, and impaired sociability (Dunn et al., ). Surprisingly, administration of the mGluR4-selective positive allosteric modulator VU0155041 (Niswender et al., ) fully rescued the behavioral abnormalities including hyperactivity, reduced anxiety, and increased compulsivity and partly suppressed the enhanced seizure susceptibility (Dunn et al., ).
Elfn1 Gene and Neuropsychiatric Disorders
Some studies using patient-derived materials have revealed the involvement of human ELFN1 in neuropsychiatric disorders. Tomioka et al. () carried out resequencing analysis of ELFN1 in patients with autism/attention-deficit hyperactivity disorder (ADHD; n = 316) and epilepsy (n = 184) as well as healthy control subjects. They identified three functional missense mutations in the patients: R650C (Asperger syndrome/ADHD), childhood absence epilepsy/ADHD (D678N), and juvenile myoclonic epilepsy (R691W). R650C and R691W are both unique (singleton); equivalent single-nucleotide polymorphisms (SNPs) have not appeared in the current dbSNP4. The frequency of D678N (rs 1186436633) is 1/125, 568, significantly rarer than that of the patient group (1/732, P = 0.011, Fisher’s exact test). Interestingly, R650C, D678N, and R691W were clustered in the cytoplasmic region. R650C, D678N, and R691W recruited significantly lower amounts of mGluR7 signal than did WT ELFN1 when expressed in hippocampal neurons. As a basis of the weaker mGluR7-recruiting ability, impaired protein trafficking was suggested for R650C and D678N (Tomioka et al., ).
In addition to ADHD/epilepsy, a recent study highlighted the involvement of ELFN1 in post-traumatic stress disorder (PTSD) pathophysiology. Girgenti et al. () performed the first transcriptome-wide analysis of gene expression changes in the postmortem brain of a large cohort of PTSD subjects. RNA-seq analysis of four prefrontal cortex subregions from 52 PTSD subjects and 46 control subjects revealed the downregulation of ELFN1 and GABA-related genes such as GAD2 (glutamate decarboxylase 2), SST, PNOC (prepronociceptin), and SLC32A1 (VGAT) in the dorsolateral prefrontal cortex (dlPFC) of PTSD patients. In a transcriptome-wide association study, they identified ELFN1 as a gene conferring significant genetic liability for PTSD (Girgenti et al., ).
Hypothetical Neural Circuits Involved in Elfn1-Associated Pathophysiology
ADHD
Dopaminergic System and SST-INs
ADHD is a neurodevelopmental disorder defined by impaired attention, disorganization, and/or hyperactivity–impulsivity (American Psychiatric Association, ). ELFN1 missense mutations (R650C and D678N) in ADHD patients and ADHD-like behavioral abnormalities in Elfn1 KO led us to hypothesize the involvement of ELFN1 in ADHD-associated neural circuits. Recent neuroimaging studies [magnetic resonance imaging (MRI), diffusion MRI, functional MRI] on ADHD patients revealed three neural circuits associated with ADHD: frontoparietal, dorsal frontostriatal, and mesocorticolimbic circuits (Gallo and Posner, ). In contrast, a genome-wide association study identified candidate genes implicated in ADHD; these included SLC6A3 (dopamine transporter), DRD4 (dopamine receptor D4), DRD5 (dopamine receptor D5), CDH13, FOXP2, DUSP6, and LPHN3 (Gallo and Posner, ; Demontis et al., ; Grimm et al., ). DUSP6 encodes a known dual-specificity protein phosphatase that decreases dopamine release in PC12 cells. Lphn3-KO rats show persistent hyperactivity, increased acoustic startle, reduced activity in response to amphetamine relative to baseline higher release of dopamine, and female-specific reduced anxiety-like behavior (Regan et al., ). Furthermore, dopamine release from Lphn3-KO rat brain slices was higher with a decreased duration and inter-event time in comparison to that from WT controls (Regan et al., ). In Lphn3-KO mice, dopamine and serotonin contents were increased in the dorsal striatum (Wallis et al., 2012), and a Gene Set Enrichment Analysis of the prefrontal cortex transcriptome found that the dopaminergic synapse pathway and the cocaine and amphetamine addiction pathways were significantly enriched (Mortimer et al., ). Taken together, these facts implicate that impaired dopamine signaling is included in the pathophysiology of LPHN3-associated ADHD.
In terms of dopamine signaling in Elfn1-KO mice, it is known that amphetamine treatment paradoxically reverses hyperactivity (Dolan and Mitchell, ). It is therefore possible that dopamine signaling is altered in the brains of Elfn1-KO mice. Further evidence linking Elfn1 function and dopaminergic neural circuits is expected.
In addition, SST-INs might be crucial in the ELFN1-associated ADHD pathophysiology. This is because SST-INs in the cerebral cortex can affect the ADHD-associated dorsal frontostriatal circuit, constituting the dorsolateral PFC, dorsal striatum, and the thalamus (Gallo and Posner, ). Supporting this idea, dysfunction of SST-INs has also been identified in another ADHD-associated gene in Cdh13-KO mice. Cdh13 is expressed by numerous parvalbumin and SST-INs located in the stratum oriens, where it localizes to both the soma and the presynaptic compartment. Cdh13-KO mice show an increase in basal inhibitory, but not in excitatory, synaptic transmission in CA1 pyramidal neurons, indicating that Cdh13 is a negative regulator of inhibitory synapses in the hippocampus (Rivero et al., ).
Significance of Habenular Circuits in ADHD
Mouse Elfn1 is expressed in habenular neurons that project to the interpeduncular nucleus (Dolan and Mitchell, ). Both the medial habenular nucleus (mHb) and lateral habenular nucleus (lHb) express high levels of Elfn1 (Figure 2C; Lein et al., ). The mHb receives synaptic inputs primarily from the septum and sends outputs through the fasciculus retroflexus into the interpeduncular nucleus, which in turn projects to raphe nuclei (Figure 2C; reviewed in Lee and Goto, ). In contrast, the lHb receives inputs from the hypothalamus, prefrontal cortex, and basal ganglia and sends outputs directly to midbrain nuclei such as the ventral tegmental area where dopaminergic neurons are located and to the dorsal raphe where serotonin neurons are located (Figure 2C; reviewed in Lee and Goto, ).
The involvement of the habenular neural circuit in ADHD pathophysiology has been suggested by both preclinical and clinical studies. Chemical or genetic disruption of the habenula has been studied in experimental animals. A neonatal habenula lesion causes hyperlocomotion, impulsivity, and attention deficits at juvenile rats, and administration of a low dose of amphetamine improves these behavioral changes (Lee and Goto, ). Genetic ablation of the mHb in mice results in reductions in interpeduncular nucleus (IPN) acetylcholine levels. These mutant mice were hyperactive, were impulsive, and displayed compulsive behaviors with deficits in long-term spatial memory (Kobayashi et al., ). In clinical terms, children with ADHD exhibit decreased habenula–putamen intrinsic functional connectivity compared to healthy controls (Arfuso et al., ). In addition, hypoactivity of the putamen has been consistently observed in medicated or medication-naïve children with ADHD (Cortese et al., ). Although further multimodal studies are needed to make a definitive conclusion, the involvement of habenular circuits in ADHD’s core pathophysiology is highly likely. Building on the habenular neural circuit physiology established by pioneering studies (Hikosaka, ; Kobayashi et al., ; Lee and Goto, ), the selective expression of Elfn1 corroborates that clarification of the role of Elfn1 in habenular neural circuits would contribute to a better understanding of ADHD pathophysiology.
Elfn1 and mGluR7 Trans-interaction and ADHD
The relationship between ELFN1 and ADHD is also supported by the genetic association of GRM7 (mGluR7) with ADHD, which has been observed in some cohorts (Elia et al., ; Park et al., ; Akutagava-Martins et al., ; Zhang et al., 2021) and with treatment response to methylphenidate among ADHD patients (Mick et al., ; Park et al., ). Furthermore, mGluR7-KO mice exhibit an attenuated response to amphetamine, with increased gamma oscillations (30–100 Hz) and lowered delta oscillations (1–3 Hz) in electroencephalography (Fisher et al., ). Amphetamines have been shown to strongly modulate gamma activity in attention-associated regions in adults with ADHD (Franzen and Wilson, ). As a possible link between Elfn1–mGluR7 trans-interaction and EEG wave control, SST- and PV-INs differentially correlate with beta (14–29 Hz) and gamma (30–100 Hz) oscillations, and they are thought to play different as well as cooperative roles in orchestrating specific cortical oscillations (Chen et al., ). Although there are no clear differences in resting-state EEG between Elfn1 KO and WT controls (Tomioka et al., ), further examination of changes to EEG in Elfn1-KO mice upon drug or environmental stimuli is of considerable value.
PTSD
The reduction of ELFN1 and SST expressions in the dlPFC of PTSD patients (Girgenti et al., ) suggests that alterations to the PFC SST-IN-containing neural circuit is included in the pathophysiology of PTSD. This idea is consistent with the results of recent neuroimaging studies on PTSD patients. dlPFC intrinsic functional connectivity is increased in PTSD patients (Li et al., ), and the dlPFC is included in frontoparietal connections (executive-control network) that are correlated with executive task performance (Seeley et al., ). It is hypothesized that disruption of the executive-control network would be included in the etiology of PTSD by top-down regulation of emotions (Abdallah et al., ; Kunimatsu et al., ). Given that the ELFN1 expression status is significantly associated with PTSD and ELFN1 expression is reduced in the dlPFC (Girgenti et al., ), ELFN1 may play a role together with other GABA-related key drivers (SST, PNOC, and GAD2) in the executive-control network.
With a candidate gene approach, genetic risk variants including monoaminergic neurotransmission-related genes (serotonin, SLC6A4; dopamine, SLC6A3, DRD2, DRD3, DBH, and COMT) were identified (Banerjee et al., ). A recent genome-wide association studies meta-analysis showed that PARK2, a dopamine regulation-related gene, is associated with PTSD (Nievergelt et al., ). Along with other accumulating evidence, dysregulation of monoaminergic transmission in PTSD pathogenesis has been hypothesized (Abdallah et al., ; Blum et al., ). In this hypothesis, monoamine dysregulation-based altered function of the dlPFC, amygdala, and striatum (Abdallah et al., ) or hypodopaminergia (low dopamine function) (Blum et al., ) is a key mediator of PTSD. Assuming the involvement of the altered dopaminergic neural circuit, Elfn1 could be associated with the PTSD pathophysiology through the habenular neural circuit as described above (see “Dopaminergic System and SST-INs” section). This idea may also be supported by the fact that ADHD and PTSD are often comorbid (Biederman et al., ; Antshel et al., ).
Epilepsy
Tomioka et al. () found functionally impaired ELFN1 mutations in epilepsy patients, D678N in an absence-type seizure patient, and R691W in a myoclonic-type seizure patient. Combined with the seizure-prone phenotype of Elfn1-KO mice, they hypothesized that a disturbed excitatory–inhibitory balance may underlie the pathophysiology (Tomioka et al., ). The dysfunction of SST-INs has been proposed as a cause of both experimental and human temporal lobe epilepsy (reviewed in Tallent and Qiu, ). Seizures induce the loss of SST-INs in the DG (Sloviter, ; Obenaus et al., ; Cossart et al., ), and there is an electrophysiologically detectable reduction in GABA release (Kobayashi and Buckmaster, ; Sun et al., ).
In terms of mGluR7 involvement in seizure, the seizure phenotype of mGluR7-KO mice is similar to that of Elfn1-KO mice as described above. In addition, a recent study identified seven deleterious mutations (I154T, W586X, R658W, R658Q, R659X, T675K, and E891K) in 11 neurodevelopmental disorder-affected patients from six unrelated families (Marafi et al., ). The three mutations (R658Q, R659X, and E891K) existed as a homozygous mutation in some patients. Of the patients’ clinical features, developmental delay, neonatal- or infantile-onset epilepsy, and microcephaly were universal. Seizure types of the affected patients were myoclonic and/or generalized tonic–clonic seizure, focal and generalized tonic–clonic seizure, and mutifocal (Marafi et al., ). These results, taken together, indicate that the deleterious impairment of mGluR7 function causes epileptic seizures both in humans and mice.
mGluR7 expression occurs broadly in excitatory neurons in the cerebral cortex and hippocampus (Lein et al., ). In agreement with its presynaptic localization, mGluR7 plays a role in the inhibition of glutamate release as an autoreceptor (reviewed in Fisher et al., ). Because of its low affinity to glutamate (high μM to mM Kd as opposed to high nM to low mM for the other group III mGluRs), mGluR7 is hypothesized to function as an “emergency brake” in the case of elevated glutamate levels (Niswender and Conn, ), explaining a context-dependent (sensory stimuli-triggered) seizure occurrence in mGluR7-KO mice (Sansig et al., ). Constitutive activation of mGluR7 by Elfn1 (Dunn et al., ; Stachniak et al., ) may also contribute to the integrity of mGluR7 function as an emergency brake. Also, in the case of Elfn1 KO, “brake failure” may well explain the sensory stimuli-triggered seizure.
Discussion
Elfn–mGluR interaction is fundamental for the tonic control of presynaptic mGluRs. However, several important questions remain unanswered. Although the possible trans-interactions between Elfns and mGluRs have been shown, the entirety of the Elfn–mGluR-associated molecular complex is not fully understood. Furthermore, the extent of the interaction occurring in the central nervous system (CNS) or peripheral organs has not been fully elucidated. Both comprehensive proteomic analyses and detailed structure analyses are necessary to determine the full extent of this interaction. The roles of Elfns in each neural circuit should be clarified through spatiotemporal gene function analysis such as conditional gene targeting. In terms of clinical relevance, the current clinical results suggest the ELFN1 is genetically associated with ADHD, PTSD, and epilepsy. However, the sample sizes and varieties in the current results are small, particularly for ADHD and epilepsy. In this regard, a candidate gene approach for various cohorts would be necessary. Knockin mice analysis would be helpful to clarify the significance of the patient-derived mutations. Finally, clarifying the roles of the Elfn–mGluR interaction in the disease-associated neural circuits is fruitful, not only for understanding the pathophysiology of the neurological disorders but also for improving our understanding of the molecular basis of higher brain functions.
Statements
Author contributions
HM and JA planned and wrote the article. All authors contributed to the article and approved the submitted version.
Funding
Many ideas in this manuscript was obtained through studies supported by KAKENHI funds (Japan Society for the Promotion of Science; 19H03327, 19K06568, and 20K21605) and grants from the Uehara Memorial Foundation and Smoking Research Foundation.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbdallahC. G.AverillL. A.AkikiT. J.RazaM.AverillC. L.GomaaH.et al. (2019). The neurobiology and pharmacotherapy of posttraumatic stress disorder. Ann. Rev. Pharmacol. Toxicol.59, 171–189. 10.1146/annurev-pharmtox-010818-021701
2
Akutagava-MartinsG. C.Salatino-OliveiraA.BruxelE. M.GenroJ. P.MotaN. R.PolanczykG. V.et al. (2014). Lack of association between the GRM7 gene and attention deficit hyperactivity disorder. Psychiatr. Genet.24, 281–282. 10.1097/YPG.0000000000000059
3
American Psychiatric Association. (2013). “Attention-deficit/hyperactivity disorder,” in Diagnostic and Statistical Manual of Mental Disorders, 5th Edn. (Arlington, VA: American Psychiatric Association), 103–106.
4
AntshelK. M.BiedermanJ.SpencerT. J.FaraoneS. V. (2014). The neuropsychological profile of comorbid post-traumatic stress disorder in adult ADHD. J. Atten. Disord.20, 1047–1055. 10.1177/1087054714522512
5
ArfusoM.SalasR.CastellanosF. X.Krain RoyA. (2019). Evidence of altered habenular intrinsic functional connectivity in pediatric ADHD. J. Atten. Disord.25, 749–757. 10.1177/1087054719843177
6
BanerjeeS. B.MorrisonF. G.ResslerK. J. (2017). Genetic approaches for the study of PTSD: Advances and challenges. Neurosci. Lett.649, 139–146. 10.1016/j.neulet.2017.02.058
7
BiedermanJ.PettyC. R.SpencerT. J.WoodworthK. Y.BhideP.ZhuJ.et al. (2013). Examining the nature of the comorbidity between pediatric attention deficit/hyperactivity disorder and post-traumatic stress disorder. Acta Psychiatr. Scand.128, 78–87. 10.1111/acps.12011
8
BlumK.Gondré-LewisM. C.ModestinoE. J.LottL.BaronD.SiwickiD.et al. (2019). Understanding the scientific basis of post-traumatic stress disorder (PTSD): precision behavioral management overrides stigmatization. Mol. Neurobiol.56, 7836–7850. 10.1007/s12035-019-1600-8
9
BruxelE. M.Moreira-MaiaC. R.Akutagava-MartinsG. C.QuinnT. P.KleinM.FrankeB.et al. (2020). Meta-analysis and systematic review of ADGRL3 (LPHN3) polymorphisms in ADHD susceptibility. Mol. Psychiatry [Online ahead of print].10.1038/s41380-020-0673-0
10
CaoY.SarriaI.FehlhaberK. E.KamasawaN.OrlandiC.JamesK. N.et al. (2015). Mechanism for selective synaptic wiring of rod photoreceptors into the retinal circuitry and its role in vision. Neuron87, 1248–1260. 10.1016/j.neuron.2015.09.002
11
CaoY.WangY.DunnH. A.OrlandiC.ShultzN.KamasawaN.et al. (2020). Interplay between cell-adhesion molecules governs synaptic wiring of cone photoreceptors. Proc. Natl. Acad. Sci. U S A117:23914. 10.1073/pnas.2009940117
12
ChenG.ZhangY.LiX.ZhaoX.YeQ.LinY.et al. (2017). Distinct inhibitory circuits orchestrate cortical beta and gamma band oscillations. Neuron96, e14061403–e14061418. 10.1016/j.neuron.2017.11.033
13
ConnP. J.PinJ. -P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharmacol. Toxicol.37, 205–237. 10.1146/annurev.pharmtox.37.1.205
14
CorteseS.KellyC.ChabernaudC.ProalE.Di MartinoA.MilhamM. P.et al. (2012). Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am. J. Psychiatry169, 1038–1055. 10.1176/appi.ajp.2012.11101521
15
CossartR.DinocourtC.HirschJ. C.Merchan-PerezA.De FelipeJ.Ben-AriY.et al. (2001). Dendritic but not somatic GABAergic inhibition is decreased in experimental epilepsy. Nat. Neurosci.4, 52–62. 10.1038/82900
16
DemontisD.WaltersR. K.MartinJ.MattheisenM.AlsT. D.AgerboE.et al. (2019). Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat. Genet.51, 63–75. 10.1038/s41588-018-0269-7
17
DolanJ.MitchellK. J. (2013). Mutation of Elfn1 in mice causes seizures and hyperactivity. PLoS One8:e80491. 10.1371/journal.pone.0080491
18
DolanJ.WalsheK.AlsburyS.HokampK.O’KeeffeS.OkafujiT.et al. (2007). The extracellular leucine-rich repeat superfamily; a comparative survey and analysis of evolutionary relationships and expression patterns. BMC Genomics8:320. 10.1186/1471-2164-8-320
19
DunnH. A.OrlandiC.MartemyanovK. A. (2019a). Beyond the ligand: extracellular and transcellular g protein-coupled receptor complexes in physiology and pharmacology. Pharmacol. Rev.71, 503–519. 10.1124/pr.119.018044
20
DunnH. A.PatilD. N.CaoY.OrlandiC.MartemyanovK. A. (2018). Synaptic adhesion protein ELFN1 is a selective allosteric modulator of group III metabotropic glutamate receptors in trans. Proc. Natl. Acad. Sci. U S A115, 5022–5027. 10.1073/pnas.1722498115
21
DunnH. A.ZuccaS.DaoM.OrlandiC.MartemyanovK. A. (2019b). ELFN2 is a postsynaptic cell adhesion molecule with essential roles in controlling group III mGluRs in the brain and neuropsychiatric behavior. Mol. Psychiatry24, 1902–1919. 10.1038/s41380-019-0512-3
22
EhrlichA. T.MaroteauxG.RobeA.VenteoL.NasseefM. T.van KempenL. C.et al. (2018). Expression map of 78 brain-expressed mouse orphan GPCRs provides a translational resource for neuropsychiatric research. Commun. Biol.1:102. 10.1038/s42003-018-0106-7
23
EliaJ.GlessnerJ. T.WangK.TakahashiN.ShtirC. J.HadleyD.et al. (2012). Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat. Genet.44, 78–84. 10.1038/ng.1013
24
FisherN. M.GouldR. W.GogliottiR. G.McDonaldA. J.BadivukuH.ChennareddyS.et al. (2020). Phenotypic profiling of mGlu7 knockout mice reveals new implications for neurodevelopmental disorders. Genes Brain Behav.19:e12654. 10.1111/gbb.12654
25
FisherN. M.SetoM.LindsleyC. W.NiswenderC. M. (2018). Metabotropic glutamate receptor 7: a new therapeutic target in neurodevelopmental disorders. Front. Mol. Neurosci.11:387. 10.3389/fnmol.2018.00387
26
FranzenJ. D.WilsonT. W. (2012). Amphetamines modulate prefrontal gamma oscillations during attention processing. Neuroreport23, 731–735. 10.1097/WNR.0b013e328356bb59
27
FredrikssonR.LagerstromM. C.LundinL. G.SchiothH. B. (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups and fingerprints. Mol. Pharmacol.63, 1256–1272. 10.1124/mol.63.6.1256
28
GacasanS. B.BakerD. L.ParrillA. L. (2017). G protein-coupled receptors: the evolution of structural insight. AIMS Biophys.4, 491–527. 10.3934/biophy.2017.3.491
29
GalloE. F.PosnerJ. (2016). Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms. Lancet Psychiatry3, 555–567. 10.1016/S2215-0366(16)00096-1
30
GirgentiM. J.WangJ.JiD.CruzD. A.AlvarezV. E.BenedekD.et al. (2021). Transcriptomic organization of the human brain in post-traumatic stress disorder. Nat. Neurosci.24, 24–33. 10.1038/s41593-020-00748-7
31
GrimmO.KranzT. M.ReifA. (2020). Genetics of ADHD: what should the clinician know?Curr. Psychiatry Rep.22:18. 10.1007/s11920-020-1141-x
32
HauserA. S.AttwoodM. M.Rask-AndersenM.SchiothH. B.GloriamD. E. (2017). Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov.16, 829–842. 10.1038/nrd.2017.178
33
HikosakaO. (2010). The habenula: from stress evasion to value-based decision-making. Nat. Rev. Neurosci.11, 503–513. 10.1038/nrn2866
34
KammermeierP. J. (2015). Constitutive activity of metabotropic glutamate receptor 7. BMC Neurosci.16:17. 10.1186/s12868-015-0154-6
35
KnappB.WolfrumU. (2016). Adhesion GPCR-related protein networks. Handb. Exp. Pharmacol.234, 147–178. 10.1007/978-3-319-41523-9_8
36
KobayashiM.BuckmasterP. S. (2003). Reduced inhibition of dentate granule cells in a model of temporal lobe epilepsy. J. Neurosci.23, 2440–2452. 10.1523/JNEUROSCI.23-06-02440.2003
37
KobayashiY.SanoY.VannoniE.GotoH.SuzukiH.ObaA.et al. (2013). Genetic dissection of medial habenula-interpeduncular nucleus pathway function in mice. Front. Behav. Neurosci.7:17. 10.3389/fnbeh.2013.00017
38
KunimatsuA.YasakaK.AkaiH.KunimatsuN.AbeO. (2019). MRI findings in posttraumatic stress disorder. J. Magn. Reson. Imaging52, 1522–2586. 10.1002/jmri.26929
39
LagerstromM. C.SchiothH. B. (2008). Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov.7, 339–357. 10.1038/nrd2518
40
LeeY. A.GotoY. (2011). Neurodevelopmental disruption of cortico-striatal function caused by degeneration of habenula neurons. PLoS One6:e19450. 10.1371/journal.pone.0019450
41
LeeY. A.GotoY. (2013). Habenula and ADHD: convergence on time. Neurosci. Biobehav. Rev.37, 1801–1809. 10.1016/j.neubiorev.2013.07.006
42
LeinE. S.HawrylyczM. J.AoN.AyresM.BensingerA.BernardA.et al. (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature445, 168–176. 10.1038/nature05453
43
LevitzJ.HabrianC.BharillS.FuZ.VafabakhshR.IsacoffE. Y. (2016). Mechanism of assembly and cooperativity of homomeric and heteromeric metabotropic glutamate receptors. Neuron92, 143–159. 10.1016/j.neuron.2016.08.036
44
LiL.LeiD.LiL.HuangX.SuoX.XiaoF.et al. (2016). White matter abnormalities in post-traumatic stress disorder following a specific traumatic event. EBioMedicine4, 176–183. 10.1016/j.ebiom.2016.01.012
45
MarafiD.MitaniT.IsikayS.HertecantJ.AlmannaiM.ManickamK.et al. (2020). Biallelic GRM7 variants cause epilepsy, microcephaly and cerebral atrophy. Ann. Clin. Transl. Neurol.7, 610–627. 10.1002/acn3.51003
46
MickE.NealeB.MiddletonF. A.McGoughJ. J.FaraoneS. V. (2008). Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet.147, 1412–1418. 10.1002/ajmg.b.30865
47
MortimerN.GansterT.O’LearyA.PoppS.FreudenbergF.ReifA.et al. (2019). Dissociation of impulsivity and aggression in mice deficient for the ADHD risk gene Adgrl3: evidence for dopamine transporter dysregulation. Neuropharmacology156:107557. 10.1016/j.neuropharm.2019.02.039
48
NievergeltC. M.MaihoferA. X.KlengelT.AtkinsonE. G.ChenC. -Y.ChoiK. W.et al. (2019). International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat. Commun.10:4558. 10.1038/s41467-019-12576-w
49
NiswenderC. M.ConnP. J. (2010). Metabotropic glutamate receptors: physiology, pharmacology and disease. Annu. Rev. Pharmacol. Toxicol.50, 295–322. 10.1146/annurev.pharmtox.011008.145533
50
NiswenderC. M.JohnsonK. A.WeaverC. D.JonesC. K.XiangZ.LuoQ.et al. (2008). Discovery, characterization and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol.74:1345. 10.1124/mol.108.049551
51
ObenausA.EsclapezM.HouserC. R. (1993). Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced seizures. J. Neurosci.13, 4470–4485. 10.1523/JNEUROSCI.13-10-04470.1993
52
O’SullivanM. L.de WitJ.SavasJ. N.ComolettiD.Otto-HittS.YatesJ. R.et al. (2012). FLRT proteins are endogenous latrophilin ligands and regulate excitatory synapse development. Neuron73, 903–910. 10.1016/j.neuron.2012.01.018
53
ParkS.JungS. W.KimB. N.ChoS. C.ShinM. S.KimJ. W.et al. (2013). Association between the GRM7 rs3792452 polymorphism and attention deficit hyperacitiveity disorder in a Korean sample. Behav. Brain Funct.9:1. 10.1186/1744-9081-9-1
54
ParkS.KimB. N.ChoS. C.KimJ. W.KimJ. I.ShinM. S.et al. (2014). The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol.24, 223–227. 10.1089/cap.2013.0079
55
RanaivosonF. M.LiuQ.MartiniF.BergamiF.von DaakeS.LiS.et al. (2015). Structural and mechanistic insights into the latrophilin3-FLRT3 complex that mediates glutamatergic synapse development. Structure23, 1665–1677. 10.1016/j.str.2015.06.022
56
ReganS. L.CryanM. T.WilliamsM. T.VorheesC. V.RossA. E. (2020). Enhanced transient striatal dopamine release and reuptake in Lphn3 knockout rats. ACS Chem. Neurosci.11, 1171–1177. 10.1021/acschemneuro.0c00033
57
ReganS. L.HufgardJ. R.PitzerE. M.SugimotoC.HuY. C.WilliamsM. T.et al. (2019). Knockout of latrophilin-3 in Sprague–Dawley rats causes hyperactivity, hyper-reactivity, under-response to amphetamine and disrupted dopamine markers. Neurobiol. Dis.130:104494. 10.1016/j.nbd.2019.104494
58
RiveroO.SeltenM. M.SichS.PoppS.BacmeisterL.AmendolaE.et al. (2015). Cadherin-13, a risk gene for ADHD and comorbid disorders, impacts GABAergic function in hippocampus and cognition. Transl. Psychiatry5, e655–e655. 10.1038/tp.2015.152
59
SandoR.JiangX.SudhofT. C. (2019). Latrophilin GPCRs direct synapse specificity by coincident binding of FLRTs and teneurins. Science363:eaav7969. 10.1126/science.aav7969
60
SansigG.BushellT. J.ClarkeV. R.RozovA.BurnashevN.PortetC.et al. (2001). Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7. J. Neurosci.21, 8734–8745. 10.1523/JNEUROSCI.21-22-08734.2001
61
SeeleyW. W.MenonV.SchatzbergA. F.KellerJ.GloverG. H.KennaH.et al. (2007). Dissociable intrinsic connectivity networks for salience processing and executive control. J. Neurosci.27, 2349–2356. 10.1523/JNEUROSCI.5587-06.2007
62
ShigemotoR.KulikA.RobertsJ. D.OhishiH.NusserZ.KanekoT.et al. (1996). Target-cell-specific concentration of a metabotropic glutamate receptor in the presynaptic active zone. Nature381, 523–525. 10.1038/381523a0
63
SloviterR. S. (1987). Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science235, 73–76. 10.1126/science.2879352
64
StachniakT. J.SylwestrakE. L.ScheiffeleP.HallB. J.GhoshA. (2019). Elfn1-induced constitutive activation of mGluR7 determines frequency-dependent recruitment of somatostatin interneurons. J. Neurosci.39, 4461–4474. 10.1523/JNEUROSCI.2276-18.2019
65
SunC.MtchedlishviliZ.BertramE. H.ErisirA.KapurJ. (2007). Selective loss of dentate hilar interneurons contributes to reduced synaptic inhibition of granule cells in an electrical stimulation-based animal model of temporal lobe epilepsy. J. Comp. Neurol.500, 876–893. 10.1002/cne.21207
66
SylwestrakE. L.GhoshA. (2012). Elfn1 regulates target-specific release probability at CA1-interneuron synapses. Science338, 536–540. 10.1126/science.1222482
67
TallentM. K.QiuC. (2008). Somatostatin: an endogenous antiepileptic. Mol. Cell. Endocrinol.286, 96–103. 10.1016/j.mce.2007.12.004
68
TomiokaN. H.YasudaH.MiyamotoH.HatayamaM.MorimuraN.MatsumotoY.et al. (2014). Elfn1 recruits presynaptic mGluR7 in trans and its loss results in seizures. Nat. Commun.5:4501. 10.1038/ncomms5501
69
WallisD.HillD. S.MendezI. A.AbbottL. C.FinnellR. H.WellmanP. J.et al. (2012). Initial characterization of mice null for Lphn3, a gene implicated in ADHD and addiction. Brain Res.1463, 85–92. 10.1016/j.brainres.2012.04.053
70
ZhangQ.ChenX.LiS.YaoT.WuJ. (2021). Association between the group III metabotropic glutamate receptor gene polymorphisms and attention-deficit/hyperactivity disorder and functional exploration of risk loci. J. Psychiatr. Res.132, 65–71. 10.1016/j.jpsychires.2020.09.035
Summary
Keywords
Elfn1, Elfn2, mGluR7, ADHD, PTSD, inhibitory interneurons, dopaminergic system, habenular circuit
Citation
Matsunaga H and Aruga J (2021) Trans-Synaptic Regulation of Metabotropic Glutamate Receptors by Elfn Proteins in Health and Disease. Front. Neural Circuit 15:634875. doi: 10.3389/fncir.2021.634875
Received
29 November 2020
Accepted
08 February 2021
Published
15 March 2021
Volume
15 - 2021
Edited by
Masahito Yamagata, Harvard University, United States
Reviewed by
Kirill Martemyanov, The Scripps Research Institute, United States; Chieko Koike, Ritsumeikan University, Japan; Kevin J. Mitchell, Trinity College Dublin, Ireland
Updates
Copyright
© 2021 Matsunaga and Aruga.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jun Aruga aruga@nagasaki-u.ac.jp
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.